Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 4,082 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

NCT00722761
View directory record Official record
Conditions
Acne Vulgaris
Interventions
drospirenone and ethinyl estradiol, Placebo tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 11, 2026, 10:53 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Inhaled Steroids on Gene Expression in the Lungs - 2

NCT00826748
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Beclomethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Calcium Supplementation for a Healthy Weight (CaSHeW)

NCT01363115
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orange Juice fortified with Calcium and Vitamin D, Orange juice without Ca or VitD, Nutritional Counseling
Dietary Supplement · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacology of 17-OHPC in Pregnancy

NCT00409825
View directory record Official record
Conditions
Pregnancy
Interventions
17-OHPC, Blood Draws
Drug · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

NCT00724568
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Doxil
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Effectiveness of Vitamin D and Repletion Strategies

NCT01524874
View directory record Official record
Conditions
Hypovitaminosis D, Insulin Resistance, Diabetes
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Kailua-Kona, Hawaii • Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

NCT00328497
View directory record Official record
Conditions
Carcinoid Tumor
Interventions
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

NCT02542410
View directory record Official record
Conditions
Endometriosis
Interventions
Cabergoline, Norethindrone acetate
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation

NCT02088931
View directory record Official record
Conditions
Late Complication From Kidney Transplant
Interventions
Treg infusion
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Short Course Glucocorticoid Treatment for PTSD

NCT00204737
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
prednisone, placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

NCT01684722
View directory record Official record
Conditions
Diabetes
Interventions
Vitamin D, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 11, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

NCT01856257
View directory record Official record
Conditions
Primary Renal Allograft Candidate, Kidney Transplantation
Interventions
Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone, basiliximab, mycophenolate mofetil, tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization

NCT00004430
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
Dihematoporphyrin derivative, prednisolone, Laser surgery
Drug · Procedure
Lead sponsor
Medical College of Hampton Roads
Other
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1998
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

NCT00061945
View directory record Official record
Conditions
Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, L1 Adult Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Adult Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
allopurinol, cyclophosphamide, daunorubicin hydrochloride, vincristine sulfate, dexamethasone, asparaginase, filgrastim, imatinib mesylate, methotrexate, cytarabine, trimethoprim-sulfamethoxazole, mercaptopurine, leucovorin calcium, alemtuzumab, acyclovir, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 11, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

NCT04300881
View directory record Official record
Conditions
Vitreomacular Traction, Subretinal Edema
Interventions
Eplerenone
Drug
Lead sponsor
Wagner Macula & Retina Center
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00100854
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, fulvestrant
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 11, 2026, 10:53 AM EDT
Recruiting Not applicable Interventional

Chronic Non-Specific Neck Pain Treated With Tai Chi and Chiropractic Care

NCT05726331
View directory record Official record
Conditions
Neck Pain, Chronic Pain
Interventions
Chiropractic Care, Tai Chi, Enhanced Usual Care
Other
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 11, 2026, 10:53 AM EDT
Not listed Phase 2 Interventional

Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

NCT00003066
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 11, 2026, 10:53 AM EDT
Recruiting Phase 3 Interventional

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
57
States / cities
Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Community Care for Croup (RCT)

NCT01042145
View directory record Official record
Conditions
Croup
Interventions
Prednisone, Dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Year to 8 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol

NCT02011828
View directory record Official record
Conditions
Inflammation, Insulin Resistance
Interventions
Ergocalciferol, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema

NCT00799227
View directory record Official record
Conditions
Diabetic Macular Edema, Vitrectomy
Interventions
Dexamethasone
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 11, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

NCT00864253
View directory record Official record
Conditions
Malignant Melanoma
Interventions
ABI-007, Dacarbazine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 11, 2026, 10:53 AM EDT